Comparative Pharmacology
Head-to-head clinical analysis: LUMIGAN versus ZIOPTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMIGAN versus ZIOPTAN.
LUMIGAN vs ZIOPTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bimatoprost is a prostamide analog that selectively mimics the effects of prostamide F2α, activating prostaglandin F (FP) receptors. It increases aqueous humor outflow through the uveoscleral pathway and may also enhance trabecular outflow, reducing intraocular pressure.
ZIOPTAN (tafluprost) is a prostaglandin analog that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
One drop of 0.01% ophthalmic solution in the affected eye(s) once daily in the evening.
250 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 78 minutes (range 54-102 minutes) in plasma after ocular administration. This short half-life reflects rapid systemic clearance, but ocular tissue levels persist longer due to local tissue binding.
Terminal elimination half-life is approximately 2.8 to 4.5 hours in patients with normal renal function; no clinically significant accumulation occurs with twice-daily dosing.
Primarily via renal elimination (approximately 67% of administered dose excreted in urine as metabolites, with less than 1% as unchanged drug). The remainder is excreted in feces (approx. 25%) via biliary elimination.
Primarily renal excretion of unchanged drug (approximately 70-80% of an administered dose recovered in urine over 48 hours); biliary/fecal excretion accounts for 13% to 20% as parent drug and metabolites.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog